Copyright Reports & Markets. All rights reserved.

Global ALK Positive Lung Cancer Treatment Market Size, Status and Forecast 2019-2025

Request for Sample of this report
Buy now

Table of Contents

    1 Report Overview

    • 1.1 Study Scope
    • 1.2 Key Market Segments
    • 1.3 Players Covered
    • 1.4 Market Analysis by Type
      • 1.4.1 Global ALK Positive Lung Cancer Treatment Market Size Growth Rate by Type (2014-2025)
      • 1.4.2 Crizotinib
      • 1.4.3 Alectinib
      • 1.4.4 Ceritinib
      • 1.4.5 Brigatinib
      • 1.4.6 Other
    • 1.5 Market by Application
      • 1.5.1 Global ALK Positive Lung Cancer Treatment Market Share by Application (2019-2025)
      • 1.5.2 Hospital
      • 1.5.3 Clinics
      • 1.5.4 Other
    • 1.6 Study Objectives
    • 1.7 Years Considered

    2 Global Growth Trends

    • 2.1 ALK Positive Lung Cancer Treatment Market Size
    • 2.2 ALK Positive Lung Cancer Treatment Growth Trends by Regions
      • 2.2.1 ALK Positive Lung Cancer Treatment Market Size by Regions (2019-2025)
      • 2.2.2 ALK Positive Lung Cancer Treatment Market Share by Regions (2014-2019)
    • 2.3 Industry Trends
      • 2.3.1 Market Top Trends
      • 2.3.2 Market Drivers
      • 2.3.3 Market Challenges
      • 2.3.4 Porter’s Five Forces Analysis

    3 Market Share by Key Players

    • 3.1 ALK Positive Lung Cancer Treatment Market Size by by Players
      • 3.1.1 Global ALK Positive Lung Cancer Treatment Revenue by by Players (2014-2019)
      • 3.1.2 Global ALK Positive Lung Cancer Treatment Revenue Market Share by by Players (2014-2019)
      • 3.1.3 Global ALK Positive Lung Cancer Treatment Market Concentration Ratio (CR5 and HHI)
    • 3.2 ALK Positive Lung Cancer Treatment Key Players Head office and Area Served
    • 3.3 Key Players ALK Positive Lung Cancer Treatment Product/Solution/Service
    • 3.4 Date of Enter into ALK Positive Lung Cancer Treatment Market
    • 3.5 Mergers & Acquisitions, Expansion Plans

    4 Breakdown Data by Type and Application

    • 4.1 Global ALK Positive Lung Cancer Treatment Market Size by Type (2014-2019)
    • 4.2 Global ALK Positive Lung Cancer Treatment Market Size by Application (2014-2019)

    5 North America

    • 5.1 North America ALK Positive Lung Cancer Treatment Market Size (2014-2019)
    • 5.2 ALK Positive Lung Cancer Treatment Key Players in North America
    • 5.3 North America ALK Positive Lung Cancer Treatment Market Size by Type
    • 5.4 North America ALK Positive Lung Cancer Treatment Market Size by Application

    6 Europe

    • 6.1 Europe ALK Positive Lung Cancer Treatment Market Size (2014-2019)
    • 6.2 ALK Positive Lung Cancer Treatment Key Players in Europe
    • 6.3 Europe ALK Positive Lung Cancer Treatment Market Size by Type
    • 6.4 Europe ALK Positive Lung Cancer Treatment Market Size by Application

    7 China

    • 7.1 China ALK Positive Lung Cancer Treatment Market Size (2014-2019)
    • 7.2 ALK Positive Lung Cancer Treatment Key Players in China
    • 7.3 China ALK Positive Lung Cancer Treatment Market Size by Type
    • 7.4 China ALK Positive Lung Cancer Treatment Market Size by Application

    8 Japan

    • 8.1 Japan ALK Positive Lung Cancer Treatment Market Size (2014-2019)
    • 8.2 ALK Positive Lung Cancer Treatment Key Players in Japan
    • 8.3 Japan ALK Positive Lung Cancer Treatment Market Size by Type
    • 8.4 Japan ALK Positive Lung Cancer Treatment Market Size by Application

    9 Southeast Asia

    • 9.1 Southeast Asia ALK Positive Lung Cancer Treatment Market Size (2014-2019)
    • 9.2 ALK Positive Lung Cancer Treatment Key Players in Southeast Asia
    • 9.3 Southeast Asia ALK Positive Lung Cancer Treatment Market Size by Type
    • 9.4 Southeast Asia ALK Positive Lung Cancer Treatment Market Size by Application

    10 India

    • 10.1 India ALK Positive Lung Cancer Treatment Market Size (2014-2019)
    • 10.2 ALK Positive Lung Cancer Treatment Key Players in India
    • 10.3 India ALK Positive Lung Cancer Treatment Market Size by Type
    • 10.4 India ALK Positive Lung Cancer Treatment Market Size by Application

    11 Central & South America

    • 11.1 Central & South America ALK Positive Lung Cancer Treatment Market Size (2014-2019)
    • 11.2 ALK Positive Lung Cancer Treatment Key Players in Central & South America
    • 11.3 Central & South America ALK Positive Lung Cancer Treatment Market Size by Type
    • 11.4 Central & South America ALK Positive Lung Cancer Treatment Market Size by Application

    12 International Players Profiles

    • 12.1 F. Hoffmann-La Roche
      • 12.1.1 F. Hoffmann-La Roche Company Details
      • 12.1.2 Company Description and Business Overview
      • 12.1.3 ALK Positive Lung Cancer Treatment Introduction
      • 12.1.4 F. Hoffmann-La Roche Revenue in ALK Positive Lung Cancer Treatment Business (2014-2019))
      • 12.1.5 F. Hoffmann-La Roche Recent Development
    • 12.2 Pfizer
      • 12.2.1 Pfizer Company Details
      • 12.2.2 Company Description and Business Overview
      • 12.2.3 ALK Positive Lung Cancer Treatment Introduction
      • 12.2.4 Pfizer Revenue in ALK Positive Lung Cancer Treatment Business (2014-2019)
      • 12.2.5 Pfizer Recent Development
    • 12.3 Novartis
      • 12.3.1 Novartis Company Details
      • 12.3.2 Company Description and Business Overview
      • 12.3.3 ALK Positive Lung Cancer Treatment Introduction
      • 12.3.4 Novartis Revenue in ALK Positive Lung Cancer Treatment Business (2014-2019)
      • 12.3.5 Novartis Recent Development
    • 12.4 TP Therapeutics
      • 12.4.1 TP Therapeutics Company Details
      • 12.4.2 Company Description and Business Overview
      • 12.4.3 ALK Positive Lung Cancer Treatment Introduction
      • 12.4.4 TP Therapeutics Revenue in ALK Positive Lung Cancer Treatment Business (2014-2019)
      • 12.4.5 TP Therapeutics Recent Development
    • 12.5 Bristol-Myers Squibb
      • 12.5.1 Bristol-Myers Squibb Company Details
      • 12.5.2 Company Description and Business Overview
      • 12.5.3 ALK Positive Lung Cancer Treatment Introduction
      • 12.5.4 Bristol-Myers Squibb Revenue in ALK Positive Lung Cancer Treatment Business (2014-2019)
      • 12.5.5 Bristol-Myers Squibb Recent Development
    • 12.6 Eli Lilly and Company
      • 12.6.1 Eli Lilly and Company Company Details
      • 12.6.2 Company Description and Business Overview
      • 12.6.3 ALK Positive Lung Cancer Treatment Introduction
      • 12.6.4 Eli Lilly and Company Revenue in ALK Positive Lung Cancer Treatment Business (2014-2019)
      • 12.6.5 Eli Lilly and Company Recent Development
    • 12.7 Takeda
      • 12.7.1 Takeda Company Details
      • 12.7.2 Company Description and Business Overview
      • 12.7.3 ALK Positive Lung Cancer Treatment Introduction
      • 12.7.4 Takeda Revenue in ALK Positive Lung Cancer Treatment Business (2014-2019)
      • 12.7.5 Takeda Recent Development
    • 12.8 Beacon Pharma
      • 12.8.1 Beacon Pharma Company Details
      • 12.8.2 Company Description and Business Overview
      • 12.8.3 ALK Positive Lung Cancer Treatment Introduction
      • 12.8.4 Beacon Pharma Revenue in ALK Positive Lung Cancer Treatment Business (2014-2019)
      • 12.8.5 Beacon Pharma Recent Development

    13 Market Forecast 2019-2025

    • 13.1 Market Size Forecast by Product (2019-2025)
    • 13.2 Market Size Forecast by Application (2019-2025)
    • 13.3 Market Size Forecast by Regions
    • 13.4 North America
    • 13.5 Europe
    • 13.6 China
    • 13.7 Japan
    • 13.8 Southeast Asia
    • 13.9 India
    • 13.10 Central & South America

    14 Analyst's Viewpoints/Conclusions

      15 Appendix

      • 15.1 Research Methodology
        • 15.1.1 Methodology/Research Approach
          • 15.1.1.1 Research Programs/Design
          • 15.1.1.2 Market Size Estimation
          • 15.1.1.3 Market Breakdown and Data Triangulation
        • 15.1.2 Data Source
          • 15.1.2.1 Secondary Sources
          • 15.1.2.2 Primary Sources
      • 15.2 Disclaimer

      ALK positive lung cancer treatment treats people get lung cancer with Anaplastic Lymphoma Kinase (ALK) mutation (the EML4-ALK fusion gene).
      In 2018, the global ALK Positive Lung Cancer Treatment market size was xx million US$ and it is expected to reach xx million US$ by the end of 2025, with a CAGR of xx% during 2019-2025.

      This report focuses on the global ALK Positive Lung Cancer Treatment status, future forecast, growth opportunity, key market and key players. The study objectives are to present the ALK Positive Lung Cancer Treatment development in North America, Europe, China, Japan, Southeast Asia, India and Central & South America.

      The key players covered in this study
      F. Hoffmann-La Roche
      Pfizer
      Novartis
      TP Therapeutics
      Bristol-Myers Squibb
      Eli Lilly and Company
      Takeda
      Beacon Pharma

      Market segment by Type, the product can be split into
      Crizotinib
      Alectinib
      Ceritinib
      Brigatinib
      Other

      Market segment by Application, split into
      Hospital
      Clinics
      Other

      Market segment by Regions/Countries, this report covers
      North America
      Europe
      China
      Japan
      Southeast Asia
      India
      Central & South America

      The study objectives of this report are:
      To analyze global ALK Positive Lung Cancer Treatment status, future forecast, growth opportunity, key market and key players.
      To present the ALK Positive Lung Cancer Treatment development in North America, Europe, China, Japan, Southeast Asia, India and Central & South America.
      To strategically profile the key players and comprehensively analyze their development plan and strategies.
      To define, describe and forecast the market by product type, market and key regions.

      In this study, the years considered to estimate the market size of ALK Positive Lung Cancer Treatment are as follows:
      History Year: 2014-2018
      Base Year: 2018
      Estimated Year: 2019
      Forecast Year 2019 to 2025
      For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.
      Buy now